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Safety and efficacy of lenalidomide in combination
with rituximab in recurrent indolent non-follicular 
lymphoma: final results of a phase II study 
conducted by the Fondazione Italiana Linfomi
The efficacy of rituximab alone in the treatment of B-cell
non-Hodgkin lymphoma (NHL) has been well estab-lished
since 1999. Furthermore, the addition of rituximab to con-
ventional chemotherapy improved survival outcome.1-3 
Lenalidomide (Celgene Corp., Summit, NJ, USA) a
potent immunomodulatory agent, has shown efficacy in
patients with relapsed or refractory indolent NHL.4 The
combination of these agents showed synergistic effects in
vitro and in animal models.5,6 Thus, in 2009, we started a
Phase II study to test the combination of rituximab and
lenalidomide in patients with marginal zone lymphoma
(MZL), lymphoplasmacytic lymphoma (LPL), and small
lymphocytic lymphoma (SLL). The study started under the
patronage of the Intergruppo Italiano Linfomi (IIL) and
was completed after the merge of the IIL in the
Fondazione Italiana Linfomi (FIL). This study was an
investigator-initiated, open label, multicenter, phase II
trial, conducted from 2009 to 2013 at 16 Italian institutions
(INFL08/RV-LYM-PI 378, clinicaltrials.gov identifier
01830478, EudraCT number 2008-001591-80). Eligibility
criteria were: age 18 years or older and biopsy-proven
diagnosis of indolent non-follicular lymphoma, including
MZL, LPL and SLL, according to the World Health
Organization Classification of Tumors of Hematopoietic
and Lymphoid Tissue.7 Patients with extranodal gastric
MZL were excluded. The inclusion criteria were: relapsed
after 2 or 3 prior lines of rituximab-containing
immunotherapy with measurable disease; Eastern
Cooperative Oncology Group performance status of 2 or
under, and adequate organ function. 
All patients provided written informed consent The
study protocol was approved by the ethics committee of
each participating institution. The study was conducted
according to the provisions of the Declaration of Hel-sinki,
the International Conference on Harmonization, and the
Guidelines for Good Clinical Practice. 
Patients received oral lenalidomide 20 mg/day; days 1-
21. Rituximab (375 mg/m2) was administered once on day
14 of every course. Treatment was repeated every 28 days
for up to 6 courses. To avoid tumor flare, patients with SLL
started lenalidomide at a dose of 10 mg/day, with a
monthly 5 mg increase, up to 20 mg/day in the absence of
toxicity.
The primary end points were safety and efficacy.
Efficacy was evaluated in terms of the overall response
rate (ORR) and of tumor control rate (TCR). ORR was
defined as the ratio between the number of patients that
achieved complete response (CR), CR unconfirmed
(CRu), and partial response (PR) over all eligible patients.
TCR was defined as the ratio between the number of
patients who achieved at least stable disease (SD) over all
the eligible patients. Both ORR and TCR were evaluated
at four weeks after the end of treatment. Tumor response
was defined according to the 1999 Cheson criteria.8
Safety was based on laboratory parameters and adverse
events. Toxicity was graded according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE version 3.0, http://ctep.can-
cer.gov/reporting/ctc.html); toxicity was reported on an indi-
vidual patient basis.
Secondary end points were progression-free survival
(PFS) duration of remission (DoR) and overall survival (OS).
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Table 1. Base-line characteristics, prior treatments and dose intensi-
ty (n=39).
N % Median 
(2.5-97.5 percentile)
Age 39 69 (51-76)
Age > 60 32 82
Sex 
Female 17 44
Histology
MZL 8 21
LPL 13 33
SLL 18 46
Immunoglobulin (g/dL)
IgG 34 0.70 (0.00-7.90)
IgA 34 0.04 (0.00-4.40)
IgM 34 0.03 (0.00-4.40)
IgM (LPL) 10 1.70 (0.55-4.40)
AA stage at diagnosis
II Bulky 3 8
III 9 23
IV 27 69
B symptoms
Yes 6 15
LDH
≤ ULN 26 67
>ULN 8 21
ND 5 13
b2 microglobulin
≤ ULN 8 24
>ULN 25 64
ND 6 15
Nodal sites
0-4 25 64
>4 14 36
Bone marrow positive
Yes 26 67
ND 5 13
MIPI-MZL
Low 3 37
Intermediate 3 37
High 1 13
ND 1 13
IPSSWM-LPL
2 3 23
3-5 8 62
ND 1 15
IPI-SLL
0-1 2 11
2 11 61
3-5 4 22
ND 1 6
N of previous treatments
2 32 82
3 7 18
Previous treatments
Rituximab 39 100
Alkylating agents 38 97
Anthracycline 20 51
Vincristine/vinblastine 16 41
Fludarabine 15 38
Bortezomib 6 14
Bendamustine 3 8
Dose intensity
Rituximab median 39 0.97(0.70-1.07)
Rituximab mean 39 0.94
Lenalidomide median 39 0.96(0.61-1.20)
Lenalidomide mean 39 0.97  
MZL: marginal zone lymphoma; LPL: lymphoplasmacytic lymphoma; SLL: small lym-
phocytic lymphoma; UNL: upper limit of normality; LDH: lactate dehydrogenase;
MIPI: Prognostic Index for Advanced Mantle Cell Lymphoma; IPSSWM: International
Prognostic Scoring System for Waldenström Macroglobulinemia; IPI: International
Prognostic Index; ND: not done. 
For this study, we planned to monitor efficacy with the
Bayesian sequential analysis,9 with a reference ORR of
45%. We screened 44 patients to achieve a final total of
40 eligible patients, considering about 10% loss of
accrued patients. 
Survival was evaluated with the Kaplan-Meier method,
and group comparisons were performed with the log
rank test. 
Safety analyses included all patients who received at
least 1 dose of study drug.
Between 2009 and 2011, 44 patients with relapsed
MZL, LPL, or SLL were screened. Five patients were
excluded from any response or survival outcome evalua-
tion: 4 had declined consent before or at the beginning of
the first cycle of therapy; 1 was excluded after a histol-
ogy-based revision of the diagnosis. Thirty-nine patients
were considered eligible and were included in the intent
to treat analysis. Base-line clinical characteristics and
prior therapies were recorded (Table 1). 
Toxicity was evaluable in 39 patients (Table 2) and
treatment was generally well tolerated. The most com-
mon serious adverse events (grade >2) were neutropenia
(56%), thrombocytopenia (10%), anemia (10%), and
infection (10%). The median duration of neutropenia,
WHO grade over 2, was 20 days (range 7-28 days). We
observed 11 (28%) cases of grade 3 non-hematologic tox-
icity, including 4 cases of infection (10%), 2 cases of fever
(5%), 1 case of tumor flare (3%), 1 case of dyspnea (3%),
1 case of renal failure (3%), 1 case of cutaneous rash
(3%), and 1 case of heart failure (3%). One patient died
of toxicity (pneumonia) during the treatment. Over
Grade 2 neutropenia was more frequent between cycles
2 to 5, and about 30% of patients required G-CSF support
during cycles 2 to 6.
Fifteen patients  had reductions in the lenalidomide
dose, 10  from 20 to 10 mg/day and 5  from 20 to 5
mg/day; furthermore, 2 patients started lenalidomide and
rituximab after a one-week delay.
Out of 39 patients, 21 patients achieved CR, CRu, or PR;
the ORR was 54% (95%CI: 37-70) and the TCR was 72%
(95%CI: 55-85). In particular, 5 (13%, 95%CI: 4-27), 2
(5%, 95%CI: 1-17), and 14 (36%, 95%CI: 21-53) patients
achieved CR, CRu, and PR, respectively. Seven patients
(18%, 95%CI: 7-34) achieved SD, and 6 patients (15%,
95%CI: 6-30) showed disease progression. Five patients
(13%, 95%CI: 4-27) withdrew from the study before the
first 3 cycles of therapy without response assessment and
were considered early failure or withdrawal. After a medi-
an follow up of 35 months (range 6-73 months), we
observed 14 (36%) deaths. The median PFS was 22
months (95%CI: 11-39) and the median DoR was 34
months (95%CI: 14 months to not assessable). The medi-
an OS was 49 months (95%CI: 35 months to not assess-
able). At two years, estimated OS, PFS, and DoR, were
78% (95%CI: 58%-89%), 45% (95%CI: 27%-62%), and
76% (95%CI: 48%-90%), respectively (Figure 1). 
The evaluation of treatment response by histology
showed an ORR of 75%, 46%, and 50% for MZL, LPL
and SLL, respectively (P=0.492).
By histology, the estimated PFSs at two years were
75% (95%CI: 31%-93%) for MZL, 54% (95%CI: 15%-
82%) for LPL, and 28% (95%CI: 9%-51%) for SLL; the
log rank test showed no significant difference between
these survival rates (P=0.144). The estimated DoR at two
years by histology was 100% for MZL, 100% for LPL,
and 51% (95%CI: 16%-82%) for SLL; the log rank test
between MZL plus LPL curve and SLL curve was margin-
ally statistically significant (P=0.056).
In a Phase II study, lenalidomide monotherapy induced
sustained responses in patients with recurrent/refractory
indolent NHL,5 and the median DoR was longer than
16.5 months. The CALGB 50401 Phase II study random-
ized 89 patients with recurrent follicular lymphoma to
lenalidomide alone or in combination with rituximab.
The combination was more active than lenalidomide
alone, showing  ORRs of 76% versus 53%, CR rates of
39% versus 20%, and event-free survivals (EFSs) of 2.0
years versus 1.2 years, respectively.10 A recently pub-
lished11 Phase II study tested lenalidomide plus rituximab
for treating relapsed/refractory indolent NHL. The results
showed an ORR of 74%, with 44% CR, and a DoR of
15.4 months. These two combination studies included 73
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Table 2. The most common adverse events associated with lenalidomide plus rituximab, graded according to the National Cancer Institute
common toxicity criteria classification (NCI CTCAE version 3.0, http://ctep.cancer.gov/reporting/ctc.html); n=39.
Grade 1/2 Grade 3 Grade 4 All Grades
Adverse events N (%) N (%) N (%) N (%)
Hematologic
Neutropenia 8 (21) 9 (23) 13 (33) 30 (77)
Anemia 23 (59) 4 (10) - - 27 (69)
Thrombocytopenia 22 (56) 3 (8) 1 (3) 26 (67)
Non-hematologic
Infections 6 (15) 3 (8) 1 (3) 10 (26)
Rash, cutaneous 8 (20) 1 (3) - - 9 (23)
Fever 6 (15) 1 (3) 1 (3) 8 (21)
Asthenia 3 (8) - - - - 3 (8)
Allergic reaction to 2 (5) - - - - 2 (5)
rituximab infusion
Gastrointestinal 2 (5) 1 (3) - - 3 (8)
Pain 2 (5) - - - - 2 (5)
Renal failure - - - - 1 (3) 1 (3)
Tumor flare - - 1 (3) - - 1 (3)
Heart failure - - 1 (3) - - 1 (3)
patients with relapsed/refractory indolent lymphoma.
Among patients, the large majority had follicular lym-
phoma (FL); only 3 patients had SLL, and one had MZL. 
Our study included 8, 13, and 18 patients with MZL,
LPL, and SLL, respectively. Patients with MZL and LPL
showed better responses, DoRs, and EFSs than patients
with SLL, and were consistent with results from a large
Phase II study conducted with previously untreated
patients with advanced-stage indolent NHL who were
treated with the lenalidomide and rituximab combina-
tion;12 the ORRs based on histology were 98%, 89%, and
80% in FL, MZL, and SLL, respectively. Similar results
were found in a study presented at the 2014 ASCO meet-
ing,13 which used the same combination of lenalidomide
and rituximab, a CR of 72% was achieved in 57 patients
with previously untreated  FL. Our results demonstrated
that patients with MZL and LPL who responded to the
combination treatment had long-lasting responses. The
combination treatment appeared to have less efficacy in
SLL. In conclusion, our findings show that the combina-
tion treatment of lenalidomide and rituximab was also
active in heavily pre-treated patients with indolent NHL 
The efficacy of this combination, in terms of either the
percentage and quality of responses or the DoR, was very
good in patients with MZL. Also, we found that the DoR
was good in patients with LPL. Of note, no previous
study has published the effects of this combination in
patients with relapsed LPL. Our results showed a mild,
predictable toxicity profile, substantially similar to those
observed in previous studies on previously untreated
patients.12-13 Our findings should be interpreted with cau-
tion because they reflect results of a multicenter Phase II
study that included a relatively low number of patients.
However, the high efficacy and relatively low toxicity of
the combination treatment in patients with indolent NHL
were previously shown in other studies, both in patients
who had relapsed and in previously untreated patients.11-
13 If these results are confirmed in Phase III trials,11-13,14
such as the pivotal NCT 01476787 trial, we may move
towards a chemotherapy-free approach in the manage-
ment of indolent NHL, which would finally turn a dream
into reality.
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Figure 1. Kaplan-Meier estimates of (A) overall survival (OS) and
(B) progression-free survival (PFS) of the 39 patients included in
the study. (C) Duration of remission (DoR) of the 21 patients who
obtained complete (CR) or partial (PR) responses at the end of
therapy. 
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